Interventional Cardiology, 2020 (vol. 19), issue 1
Slovo úvodem
Martin Mates, Petr Kala
Interv Akut Kardiol. 2020;19(1):8 
Historie demonstračních seminářů intervenční kardiologie
Jan F. Vojáček
Interv Akut Kardiol. 2020;19(1):10-13 | DOI: 10.36290/kar.2020.012
Střípky z historie katetrizačních vyšetření v Hradci Králové
Vladimír Rozsíval
Interv Akut Kardiol. 2020;19(1):14-16 | DOI: 10.36290/kar.2020.013
Transcatheter closure of patent foramen ovale - position paper of Czech association of interventional cardiology, Czech neurological society and Czech association of cardiac imaging of Czech society of cardiology
Ivo Varvařovský, Martin Mates, David Horák, Martin Polozcek, Josef Šťásek, Tomáš Mráz, Viktor Kočka, Michael Želízko, Ivo Bernat, Marian Branny, Pavel Červinka, Petr Kala, Petr Kmoníček, Tomáš Kovárník, Ladislav Pešl
Interv Akut Kardiol. 2020;19(1):18-23 | DOI: 10.36290/kar.2020.014
Development of percutaneous coronary interventions in the Czech Republic in 2005-2018. Results of the National Registry of Cardiovascular Interventions
Michael Želízko, Světlana Drábková, Ingrid Kováčová, Martin Mates
Interv Akut Kardiol. 2020;19(1):25-29 | DOI: 10.36290/kar.2020.015
The National Registry of Cardiovascular Interventions (NRKI) is a prospective multicentre registry that collects data on all percutaneous coronary interventions (PCIs) performed from all PCI centers in the Czech Republic, prospectively since 2005. In the period 2005-2017, it is noticeable (approx. 14 %) an increase in the number of patients treated and PCIs performed. The proportion of men and women does not change substantially (70 : 30), the average age of patients is increasing, more for men than for women. PCI for ACS has been around 50 % in the long term, with primary PCI in the acute phase of STEMI around 6,000 patients annually - even the number...
State-of-the-art PCI for coronary artery chronic total occlusion
Vojtěch Novotný
Interv Akut Kardiol. 2020;19(1):31-38 | DOI: 10.36290/kar.2020.016
PCI for chronic total occlusion (CTO) of coronary arteries is one of the most dynamically developing fields in interventional cardiology. The issue itself involves some controversy. These are very complex procedures which, on the one hand, can significantly improve the quality of life of many patients, but on the other hand, are burdened by a higher risk of periprocedural complications compared to common non-CTO PCI. The fact that, even in our conditions, dedicated CTO programmes with increasing numbers of these procedures were set up at some centres implies that it is a current issue. The review article presents an abridged version of a state-of-the-art...
Functional myocardial revascularization
Tomáš Kovárník, Štěpán Jeřábek, Petr Kala
Interv Akut Kardiol. 2020;19(1):39-46 | DOI: 10.36290/kar.2020.017
The concept of functional revascularization has been broadly accepted. Although the best clinical evidence has been provided in patients with chronic coronary syndromes, recent data strongly advocate its use also in patients with acute coronary syndromes. Invasive pressure-derived indexes: hyperemic FFRmyo (myocardial fractional flow reserve) and resting iFR (instantaneous free ratio) or others require an interventional procedure by wiring the diseased vessel. Values of FFRmyo ≤ 0.80 and of iFR ≤ 0.89 are suggestive of functionally significant coronary disease mostly indicated for revascularization. Moreover there are several...
Antithrombotic therapy after percutaneous and surgical interventions on valves
Marian Branny
Interv Akut Kardiol. 2020;19(1):48-52 | DOI: 10.36290/kar.2020.018
Surgical and catheter interventions on stenotic or insufficient valves are the only acknowledged effective treatment for patients with a haemodynamically significant defect. Interventional valve repair carries a risk of both thrombotic and bleeding complications. Although antithrombotic drugs reduce the risks of interventional treatment, an optimal therapeutic regimen and treatment duration remain unknown. This article presents an overview of recent information on this issue as well as a review of current evidence on antithrombotic therapy following interventional treatment for valvular heart disease.
Infective endocarditis in transcatheter aortic valve implantation
Miroslav Brtko
Interv Akut Kardiol. 2020;19(1):55-59 | DOI: 10.36290/kar.2019.053
Since the first transcatheter aortic valve implantation (TAVI) this method has spread out widely. Originally, this method was indicated for inoperable and high-risk patients; nowadays it has FDA approval even for low-risk patients. As any invasive procedure, TAVI is also associated with complications, including prosthetic valve endocarditis (TAVI-IE). The incidence of TAVI-IE is reported to be 0.2-3.4 % and its mortality up to 67 % at two years after confirmation of the diagnosis. The aim of this article is to review current knowledge on this serious complication.
Allergic reactions after ASD/PFO occluder implantation
Aneta Dvořáková, Karel Kopřiva, Martin Mates
Interv Akut Kardiol. 2020;19(1):60-62 | DOI: 10.36290/kar.2020.019
The authors present currently available information regarding allergic reactions after catheter closure of atrial septal defects. The pathogenesis of the reaction, possible types of undesirable allergic complications and their management are described.
Cangrelor (KENGREXAL®): a new old acquintance
Ivo Varvařovský
Interv Akut Kardiol. 2020;19(1):63-66 | DOI: 10.36290/kar.2020.020
Cangrelor is the only intravenous platelet P2Y12 receptor inhibitor with proven clinical efficacy for the reduction of PCI - related ischemic complications. Cangrelor pharmacology, clinical studies, and off-label indications are disscused in this review article.
Transcarotid TAVR: a safe alternative for patients with other vascular access
Pavel Červinka, Radim Špaček, Petr Vojtíšek, Robert Bartoš
Interv Akut Kardiol. 2020;19(1):68-71 | DOI: 10.36290/kar.2020.021
The authors present a case report of transcarotid TAVR in female patient with no possibility to perform a procedure via other vascular access.
Jubilant doc. MUDr. Ivo Bernat, Ph.D.
prof. MUDr. Richard Rokyta, Ph.D.
Interv Akut Kardiol. 2020;19(1):73-74